SI2782602T1 - Nukleotid DIMS0-150 za uporabo pri zdravljenju kroničnega aktivnega ulcerativnega kolitisa - Google Patents

Nukleotid DIMS0-150 za uporabo pri zdravljenju kroničnega aktivnega ulcerativnega kolitisa

Info

Publication number
SI2782602T1
SI2782602T1 SI201231671T SI201231671T SI2782602T1 SI 2782602 T1 SI2782602 T1 SI 2782602T1 SI 201231671 T SI201231671 T SI 201231671T SI 201231671 T SI201231671 T SI 201231671T SI 2782602 T1 SI2782602 T1 SI 2782602T1
Authority
SI
Slovenia
Prior art keywords
dims0
nucleotide
treatment
ulcerative colitis
chronic active
Prior art date
Application number
SI201231671T
Other languages
English (en)
Slovenian (sl)
Inventor
Charlotte Admyre
Arezou Zargari
Stein Oliver Von
Stein Petra Von
Original Assignee
Index Pharmaceuticals Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Index Pharmaceuticals Ab filed Critical Index Pharmaceuticals Ab
Publication of SI2782602T1 publication Critical patent/SI2782602T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SI201231671T 2011-11-25 2012-11-23 Nukleotid DIMS0-150 za uporabo pri zdravljenju kroničnega aktivnega ulcerativnega kolitisa SI2782602T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP11190826.5A EP2596806A1 (en) 2011-11-25 2011-11-25 Method for prevention of colectomy
US201261595230P 2012-02-06 2012-02-06
EP12790904.2A EP2782602B1 (en) 2011-11-25 2012-11-23 Nucleotide DIMS0-150 for use in the treatment of chronic active ulcerative colitis
PCT/EP2012/073501 WO2013076262A1 (en) 2011-11-25 2012-11-23 Method for prevention of colectomy

Publications (1)

Publication Number Publication Date
SI2782602T1 true SI2782602T1 (sl) 2019-11-29

Family

ID=45094516

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201231671T SI2782602T1 (sl) 2011-11-25 2012-11-23 Nukleotid DIMS0-150 za uporabo pri zdravljenju kroničnega aktivnega ulcerativnega kolitisa

Country Status (16)

Country Link
US (3) US9492516B2 (enExample)
EP (3) EP2596806A1 (enExample)
JP (2) JP6193248B2 (enExample)
CA (1) CA2892203C (enExample)
CY (1) CY1122089T1 (enExample)
DK (1) DK2782602T3 (enExample)
ES (1) ES2745677T3 (enExample)
HR (1) HRP20191723T1 (enExample)
HU (1) HUE046154T2 (enExample)
LT (1) LT2782602T (enExample)
PL (1) PL2782602T3 (enExample)
PT (1) PT2782602T (enExample)
RS (1) RS59358B1 (enExample)
SI (1) SI2782602T1 (enExample)
SM (1) SMT201900527T1 (enExample)
WO (1) WO2013076262A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2881808C (en) * 2013-07-05 2021-08-17 Sony Corporation Transmission apparatus, transmission method, reception apparatus, and reception method
US20180193270A1 (en) 2016-11-29 2018-07-12 PureTech Health LLC Exosomes for delivery of therapeutic agents
BR112019021520A2 (pt) 2017-04-14 2020-08-04 Tollnine, Inc. oligonucleotídeo, composto, polinucleotídeo imunomodulador, composição, conjugado, método para modular um receptor, método de tratamento de um tumor, método de tratamento de câncer, método para tratar um tumor, método de prevenção de câncer, método para induzir uma resposta imune
GB201707503D0 (en) * 2017-05-10 2017-06-21 Index Pharmaceuticals Ab New Therapy 3
GB201707501D0 (en) * 2017-05-10 2017-06-21 Index Pharmaceuticals Ab New therapy 2
GB201807312D0 (en) 2018-05-03 2018-06-20 Index Pharmaceuticals Ab Formulation
GB201818579D0 (en) * 2018-11-14 2018-12-26 Index Pharmaceuticals Ab New therapy
GB201912191D0 (en) * 2019-08-24 2019-10-09 Index Pharmaceuticals Ab New therapy
EP4147688A1 (en) * 2021-09-09 2023-03-15 InDex Pharmaceuticals AB Enema formulation

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5149797A (en) 1990-02-15 1992-09-22 The Worcester Foundation For Experimental Biology Method of site-specific alteration of rna and production of encoded polypeptides
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
US5849719A (en) 1993-08-26 1998-12-15 The Regents Of The University Of California Method for treating allergic lung disease
AU713040B2 (en) 1994-07-15 1999-11-18 University Of Iowa Research Foundation, The Immunomodulatory oligonucleotides
CA2244946C (en) 1996-01-30 2010-04-13 The Regents Of The University Of California Gene expression vectors which generate an antigen specific immune response and methods of using the same
WO1998016247A1 (en) 1996-10-11 1998-04-23 The Regents Of The University Of California Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6426334B1 (en) 1997-04-30 2002-07-30 Hybridon, Inc. Oligonucleotide mediated specific cytokine induction and reduction of tumor growth in a mammal
EP1003531B1 (en) 1997-05-20 2007-08-22 Ottawa Health Research Institute Processes for preparing nucleic acid constructs
US6809193B2 (en) * 1997-08-13 2004-10-26 Isis Pharmaceuticals, Inc. Antisense oligonucleotide compositions and methods for the modulation of JNK proteins
JP2008526249A (ja) 2005-01-13 2008-07-24 プロジェニカ・バイオファーマ・エス・アー ｉｎｖｉｔｒｏ遺伝子タイピングのための方法および製品
EP1892293A4 (en) 2005-06-06 2008-12-10 Anges Mg Inc TRANSCRIPTION FACTOR DECOY
PT2179737E (pt) 2005-07-01 2013-12-05 Index Pharmaceuticals Ab Método para modular a capacidade de resposta aos esteróides
SI2380584T1 (sl) * 2005-07-01 2014-04-30 Index Pharmaceuticals Ab Imunostimulatorni postopek
ES2560782T3 (es) * 2008-11-04 2016-02-22 Index Pharmaceuticals Ab Compuestos y métodos para el tratamiento de enfermedades inflamatorias del SNC

Also Published As

Publication number Publication date
EP2596806A1 (en) 2013-05-29
CA2892203C (en) 2021-11-16
JP2017061508A (ja) 2017-03-30
US20170014442A1 (en) 2017-01-19
JP6318221B2 (ja) 2018-04-25
LT2782602T (lt) 2019-10-10
WO2013076262A1 (en) 2013-05-30
US9492516B2 (en) 2016-11-15
EP2782602B1 (en) 2019-06-26
JP2015504438A (ja) 2015-02-12
PT2782602T (pt) 2019-10-14
US20180015117A1 (en) 2018-01-18
ES2745677T3 (es) 2020-03-03
DK2782602T3 (da) 2019-09-30
RS59358B1 (sr) 2019-11-29
EP3556403A1 (en) 2019-10-23
EP2782602A1 (en) 2014-10-01
US9795627B2 (en) 2017-10-24
PL2782602T3 (pl) 2019-12-31
SMT201900527T1 (it) 2019-11-13
US20150004187A1 (en) 2015-01-01
HUE046154T2 (hu) 2020-02-28
CA2892203A1 (en) 2013-05-30
CY1122089T1 (el) 2020-11-25
JP6193248B2 (ja) 2017-09-06
HRP20191723T1 (hr) 2019-12-13

Similar Documents

Publication Publication Date Title
GB2484598B (en) Improvements in catheters
PL2782602T3 (pl) Nukleotyd DIMS0-150 do zastosowania w leczeniu przewlekłego aktywnego wrzodziejącego zapalenia jelita grubego
GB201115711D0 (en) Phyto-cannabinoids for use in the treatment of cancer
ZA201307797B (en) Bicyclic heterocycle compounds and their uses in therapy
IL230698A0 (en) Use of preparations containing crizotinib to treat cancer
GB2487248B (en) Water treatment
GB2489037B (en) Integrated water treatment system
GB2487247B (en) Water treatment
GB2487246B (en) Water treatment
PL2726557T3 (pl) Środek do obróbki powierzchniowej o wysokich właściwościach fotokatalitycznych i sanitarnych
GB201110781D0 (en) Liquid treatment systems
ZA201307058B (en) Use of polyaminoisoprenyl derrivatives in antobiotic or antisertic treatment
GB2515440B (en) Vesicular Formulations for use in the treatment of Rosacea
ZA201307760B (en) Treatment regimens
PL2734634T3 (pl) Igf-1 do zastosowania do leczenia migreny
GB2487249B (en) Water treatment
IL230746A0 (en) 2-aldh inhibitors in the treatment of addiction
EP2704731A4 (en) TREATMENT OF AVIAN ORIGIN
GB201116411D0 (en) Water treatment
GB201116410D0 (en) Water treatment
GB201121044D0 (en) Treatment of solutions
GB201113479D0 (en) Finishing treatment
ZA201406351B (en) Combination treatment (eg. with abt-072 or abt -333) of daaas for use in theating hvc
GB201102267D0 (en) Treatment
GB201102269D0 (en) Treatment